Investing

In the high-stakes world of finance, few narratives are as inspiring as that of Kathryn Glass, co-head of the high-yield fixed-income group at Federated Hermes. With over 27 years of experience, Glass transitioned from the realm of Japan’s literary culture to the complexities of finance, embodying resilience and adaptability. Her journey illustrates not just personal
0 Comments
Since the tariffs were implemented under the Trump administration, a palpable tension has gripped the financial markets. There’s an unmistakable anxiety that these protective measures might stifle demand, ultimately steering the economy toward a downturn. This concern reverberates through the stock market, creating a climate of volatility that can feel relentless. Yet, amidst the chaos,
0 Comments
Investors find themselves in a perplexing environment as we approach the second quarter of the year. With whispers of a looming trade war resonating through financial corridors and economic data offering conflicting signs, the stock market’s volatility has sparked both fear and hesitation. Recent reports highlighting that February’s core personal consumption expenditures price index—often cited
0 Comments
In a rapidly shifting economic landscape, where inflationary pressures and tariff uncertainties loom large, one must examine the market from a more strategic perspective. Chief market strategist Gina Sanchez of Lido Advisors highlights the potential resilience of discount retailers like Dollar General in the face of weakening consumer confidence. With projections of slowed economic growth
0 Comments
The recent turbulence in the stock market has left many investors scrambling for answers. President Donald Trump’s new tariff policies, coupled with data suggesting a faltering economy, have created a cocktail of uncertainty that rattled even the staunchest market enthusiasts. Yet amidst this chaos, there lies a golden opportunity, one that discerning investors should seize
0 Comments
Recent moves by the Trump administration to slash funding from the National Institutes of Health (NIH) have sent shockwaves through the scientific community and rippled out to the broader marketplace. Capping indirect costs at 15%—well below industry standards—poses a significant financial threat not just to research institutions but to life sciences companies tied closely to
0 Comments